As a way to rein in the staggering amount of money that Americans spend on the complex drugs known as biologics each year, creating biosimilars as less-expensive alternatives makes sense. Europe has already approved 43 biosimilars; the U.S. just 11 of them. The U.S. will continue to lag behind in the development and use of biosimilars if Congress and the FDA require the “interchangeability” label for pharmacy substitution of reference biologics.

This interchangeability requirement is misguided on several levels, is counterproductive for the adoption of biosimilars, and will force Americans to pay billions of dollars more for these specialty drugs than they need to. The FDA’s role is to regulate drug approvals, not the practice of medicine, which it is veering into with the interchangeability requirement.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Well argued commentary.
    Interchangeability/substitution labeling might be needed to distinguish between Adverse Reactions to originator/biosimilar products.
    However, I am not aware of any reports of immunogenicity related safety issues for any of the biosimilar products approved in the EU, and it is very unlikely that there will be any in the future, considering the long time that the EMA has been monitoring the use of biosimilars in the EU.
    It seems likely to me that the interchangeability classification in the US is just the FDA responding to powerful lobbying by the US biopharma industry….

  • All fair points made in this article. The problem is a “new to market” biosimilar has no market share and a low list price so no PBM would ever substitute it for a more lucrative originator, interchangeable or not. Gov’t insurance could attempt this; but the middleman (PBM) that values higher list price drugs would need to be removed from the equation.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy